Abstract:Up to 25,000 people die each year from resistant infections in Europe alone, with increasing incidence. It is estimated that a continued rise in bacterial resistance by 2050 would lead up to 10 million annual deaths worldwide, exceeding the incidence of cancer deaths. Although the design of new antibiotics is still one way to tackle the problem, pharmaceutical companies investigate far less into new drugs than 30 years ago. Incorporation of antibiotics into nanoparticle drug carriers ("nanoantibiotics") is currently investigated as a promising strategy to make existing antibiotics regain antimicrobial strength and overcome certain types of microbial drug resistance. Many of these synthetic systems enhance the antimicrobial effect of drugs by protecting antibiotics from degradation and reducing their side effects. Nevertheless, they often cannot selectively target pathogenic bacteria and - due to their synthetic origin - may induce side-effects themselves. In this work, we present the characterisation of naturally derived outer membrane vesicles (OMVs) as biocompatible and inherently antibiotic drug carriers. We isolated OMVs from two representative strains of myxobacteria, Cystobacter velatus Cbv34 and Sorangiineae species strain SBSr073, a bacterial order with the ability of lysing other bacterial strains and currently investigated as sources of new secondary metabolites. We investigated the myxobacterias' inherent antibacterial properties after isolation by differential centrifugation and purification by size-exclusion chromatography. OMVs have an average size range of 145-194 nm. We characterised their morphology by electron cryomicroscopy and found that OMVs are biocompatible with epithelial cells and differentiated macrophages. They showed a low endotoxin activity comparable to those of control samples, indicating a low acute inflammatory potential. In addition, OMVs showed inherent stability under different storage conditions, including 4 °C, -20 °C, -80 °C and freeze-drying. OMV uptake in Gram-negative model bacterium Escherichia coli (E. coli) showed similar to better incorporation than liposome controls, indicating the OMVs may interact with model bacteria via membrane fusion. Bacterial uptake correlated with antimicrobial activity of OMVs as measured by growth inhibition of E. coli. OMVs from Cbv34 inhibited growth of E. coli to a comparable extent as the clinically established antibiotic gentamicin. Liquid-chromatography coupled mass spectrometry analyses revealed the presence of cystobactamids in OMVs, inhibitors of bacterial topoisomerase currently studied to treat different Gram-negative and Gram-positive pathogens. This work, may serve as an important basis for further evaluation of OMVs derived from myxobacteria as novel therapeutic delivery systems against bacterial infections.

Enzyme‐Responsive Polymeric Vesicles for Bacterial‐Strain‐Selective Delivery of Antimicrobial Agents

Polymeric Nanoplatforms for the Delivery of Antibacterial Agents

Formulation of pH-responsive PEGylated nanoparticles with high drug loading capacity and programmable drug release for enhanced antibacterial activity

Injectable Phage-Loaded Microparticles Effectively Release Phages to Kill Methicillin-Resistant <i>Staphylococcus aureus</i>

Biodegradable nanostructures with selective lysis of microbial membranes

Lipase and pH-responsive diblock copolymers featuring fluorocarbon and carboxyl betaine for methicillin-resistant staphylococcus aureus infections

Infection Microenvironment-Responsive Multifunctional Peptide Coated Gold Nanorods For Bimodal Antibacterial Applications

Poly(amino acid)-based drug delivery nanoparticles eliminate Methicillin resistant Staphylococcus aureus via tunable release of antibiotic

A Ph and Hyaluronidase Dual-Responsive Multilayer-Based Drug Delivery System for Resisting Bacterial Infection

Addressing MRSA infection and antibacterial resistance with peptoid polymers

pH‐Responsive Polymer–Drug Conjugate: An Effective Strategy to Combat the Antimicrobial Resistance

Dual Drug Loaded pH-sensitive Micelles for Efficient Bacterial Infection Treatment

Dual osmotic controlled release platform for antibiotics to overcome antimicrobial-resistant infections and promote wound healing

Pyramid-Shaped PEG-PCL-PEG Polymeric-Based Model Systems for Site-Specific Drug Delivery of Vancomycin with Enhance Antibacterial Efficacy

Evaluation of hypocrellin A-loaded lipase sensitive polymer micelles for intervening methicillin-resistant Staphylococcus Aureus antibiotic-resistant bacterial infection

Redox-responsive degradation of antimicrobials with programmable drug release for enhanced antibacterial activity

Targeted polymer-based antibiotic delivery system: A promising option for treating bacterial infections via macromolecular approaches

A macromolecular approach to eradicate multidrug resistant bacterial infections while mitigating drug resistance onset

Self-Assembling and Pore-Forming Peptoids as Antimicrobial Biomaterials

Biocompatible bacteria-derived vesicles show inherent antimicrobial activity

The controlled drug release by pH-sensitive molecularly imprinted nanospheres for enhanced antibacterial activity.